Literature DB >> 29390362

Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Giuseppe Corrias1, Natally Horvat, Serena Monti, Olca Basturk, Oscar Lin, Luca Saba, Lisa Bodei, Diane L Reidy, Lorenzo Mannelli.   

Abstract

RATIONALE: Glucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process. PATIENT CONCERNS: We report a case of a 68-year-old woman with a pancreatic glucagonoma. Her symptoms at the onset were typical of the glucagonoma syndrome. DIAGNOSES: After a significant weight loss, she underwent a computer tomography scan of the abdomen, which showed a hypervascular lesion of the tail of the pancreas and hypervascular lesions of the liver. An ultrasound guided biopsy was performed and pathology was consistent with glucagonoma. Her blood glucagon levels were elevated. OUTCOMES: She was treated with chemotherapy and somatostatin analogs. After 4 years, the disease had a malignant transformation, and metastases suddenly started to grow up. She stopped being responsive to treatment and eventually passed away. LESSONS: Due to its rarity, clinical diagnosis is challenging and generally it comes after a long interval since the onset of symptoms. Awareness of physicians and dermatologists of the characteristic necrolytic migratory erythema, and of the other symptoms, often leads to early diagnosis.
Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29390362      PMCID: PMC5815774          DOI: 10.1097/MD.0000000000009252

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  27 in total

1.  A pregnant patient with hypoglycemia.

Authors:  Lorenzo Mannelli; Matthew M Yeh; Carolyn L Wang
Journal:  Gastroenterology       Date:  2012-08-23       Impact factor: 22.682

2.  Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry.

Authors:  Nathalie Lévy-Bohbot; Corinne Merle; Pierre Goudet; Brigitte Delemer; Alain Calender; Damien Jolly; Gérard Thiéfin; Guillaume Cadiot
Journal:  Gastroenterol Clin Biol       Date:  2004-11

3.  Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.

Authors:  Ka Kit Wong; Elizabeth A Wynn; Jamie Myles; Robert J Ackermann; Kirk A Frey; Anca M Avram
Journal:  Clin Nucl Med       Date:  2011-01       Impact factor: 7.794

4.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

5.  Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.

Authors:  Roy Eldor; Benjamin Glaser; Merav Fraenkel; Victoria Doviner; Asher Salmon; David J Gross
Journal:  Clin Endocrinol (Oxf)       Date:  2011-05       Impact factor: 3.478

6.  Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.

Authors:  William Makis; Karey McCann; Terence A Riauka; Alexander J B McEwan
Journal:  Clin Nucl Med       Date:  2015-11       Impact factor: 7.794

7.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Authors:  Stefano Severi; Oriana Nanni; Lisa Bodei; Maddalena Sansovini; Annarita Ianniello; Stefania Nicoletti; Emanuela Scarpi; Federica Matteucci; Laura Gilardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-27       Impact factor: 9.236

8.  Clinical and metabolic aspects of glucagonoma.

Authors:  S B Leichter
Journal:  Medicine (Baltimore)       Date:  1980-03       Impact factor: 1.889

Review 9.  Glucagonoma syndrome: a review and update on treatment.

Authors:  A M John; R A Schwartz
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-07-16       Impact factor: 6.166

10.  Population-based study of islet cell carcinoma.

Authors:  James C Yao; Milton P Eisner; Colleen Leary; Cecile Dagohoy; Alexandria Phan; Asif Rashid; Manal Hassan; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.